William Blair analyst Myles Minter has maintained their bullish stance on DNTH stock, giving a Buy rating on February 11.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Myles Minter has given his Buy rating due to a combination of factors tied to the advancement and breadth of Dianthus’s lead asset, claseprubart. He highlights the upcoming interim responder analysis from the open-label Phase II CAPTIVATE trial in CIDP, viewing this readout as a key value inflection point for what he sees as a potentially best-in-class C1s inhibitor in a high-need autoimmune neurology indication.
In addition, Minter notes that claseprubart has already generated strong placebo-controlled Phase II data in gMG, reinforcing its profile as a competitive complement-pathway therapy, while also flagging the underrecognized upside in MMN with pivotal MoMeNtum data expected in 2026. Taken together, the multi-indication strategy, favorable early efficacy signals, and looming clinical catalysts underpin his constructive stance and support a Buy recommendation on DNTH.
In another report released on February 11, Wedbush also maintained a Buy rating on the stock with a $55.00 price target.
DNTH’s price has also changed dramatically for the past six months – from $20.850 to $47.400, which is a 127.34% increase.